Low-dose radiation plus immunotherapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests a new way to treat nasopharyngeal cancer that has spread, using a special type of radiation plus an immunotherapy drug. It is for people who cannot or choose not to have chemotherapy, and it aims to control the cancer while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have nasopharyngeal cancer that has spread to other parts of the body, with 10 or fewer spots of spread.
- You must have a tumor test showing a 'CPS' score of 1 or higher (a marker that may predict response to immunotherapy).
- You must not be able to receive or have decided against standard chemotherapy for this cancer.
- You must be in generally good health, with adequate organ function, and able to care for yourself (ECOG 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an extra treatment after standard chemoradiation can reduce the chance of nasopharyngeal cancer coming back. The new treatment combines an immunotherapy drug (sintilimab) with a chemotherapy pill (capecitabine) for a year.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This study tests two immunotherapy drugs together for people whose nasopharyngeal cancer has continued to grow after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests whether adding an immunotherapy drug called sintilimab to standard chemoradiotherapy (chemo and radiation) is better than chemoradiotherapy alone for a specific type of nasopharyngeal cancer that has spread to neck lymph nodes. Immunotherapy uses your own immune system to fight cancer, and the hope is that adding it before and after standard treatment can improve outcomes.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.